Recent Winners On GuerillaStockTrading

Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days
Alert Price: $19.94
High Price: $20.75
Results: 4% in 13 Days
Alert Price: $31.53
High Price: $32.69
Results: 4% in 9 Days
Alert Price: $14.05
High Price: $14.55
Results: 4% in 21 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

Top Catalysts For The Week Ending January 20 2017

Sanchez Energy = Eagleford Acquisition Doubles Drilling Inventory

Mobileye = Goldman Sachs Raised Mobileye To A Buy Rating

Tesla = Expanding Investment In Gigafactory by $350 Million, Adding 550 New Jobs To Make Model 3

AbbVie = Gets FDA Approval For Imbruvica

3D Systems = Hearing Takeover Rumors Circulating About GE

International Game Technology = Wins Big Contract From Svenska Spel in Sweden

WiLAN = Court of Appeals Grants WiLAN Positive Rulings In Case Against Ericsson

Gilead Sciences = Hearing Takeover Rumors Circulating

Juno = Hearing Juno Takeover Rumors Circulating

Fusion Telecommunications = Awarded 3-year $100K For Managed Cloud Services

Teva Pharmaceutical = Receives FDA Approval For Vantrela ER

EPAM Systems = Lands Giant UBS Multi-year Agreement Valued At Over $300 Million

Tutor Perini Building = Receives Notice of Intent To Award a $1.37 Billion Contract From Los Angeles County

Amicus Therapeutics = Hearing Takeover Rumors Circulating

CEMEX = Trump Build That Wall Play

Iridium Communications = Announces Successful First Launch For Space-Based ADS-B Network

Applied Optoelectronics = Play On Switch From Copper To Optical Interconnect Inside Datacenters

3D Systems = Expands its Virtual Surgical Planning Service to Include Cranial Applications


Trading Lessons

Mainstream Financial News


Alexion Pharmaceuticals Seeing Heavy Call Activity

Follow Us on StockTwits

January 4, 2017: Seeing heavy call activity in Alexion Pharmaceuticals: 2,000 Aug $140 calls traded at $12.80. I wonder if the heavy call activity has anything to do with the takeover rumors that were circulating on December 20, 2016, about Alexion Pharmaceuticals?

December 22, 2016: Leerink defending Alexion Pharmaceuticals; Reiterates outperform rating and price target of $211. Leerink says that the failure of Soliris for the prevention of delayed graft function (DGF) after kidney transplantation does not materially impact firms long-term Soliris forecasts or growth rate, but does represent another example of Alexion ploughing Soliris profits into high risk trials for low value indications. DGF represented less than $50M of annual global sales for their long-term Soliris forecasts (previous probability of success was 35%), and the removal does not impact firms valuation.

December 20, 2016: Hearing takeover rumors circulating about biotechnology firm Alexion Pharmaceuticals. The rumor is that a big (but unnamed) drug company has approached Alexion Pharmaceuticals with a takeover offer. The rumor is that Roche could be still interested in Alexion. The rumors are likely coming from this story:

I put a lot of credibility on this takeover rumor because the CEO Hallal left the company on 12/12/16 for “personal reasons” and CFO Sinha also left the company to “pursue other opportunities.” Sometimes when high-ranking officers in a company start leaving all of a sudden, something big is going on.

Alexion Pharmaceuticals Stock Chart

The Finviz screener settings used to find Alexion Pharmaceuticals are: Sector Healthcare, Sales growth past 5 years Over 30%, EPS growth qtr over qtr 100% – 200%, Gross Margin High (>50%)

Alexion is a biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation, development, and commercialization of life-transforming therapeutic products.


Trading The News: Alexion Pharmaceuticals In The News